Acute Lymphoblastic Leukemia Therapeutics Market
The global acute lymphoblastic leukemia therapeutics market is expected to register a CAGR of approximately 5.2% during the forecast period (2018 - 2023). Acute lymphoblastic leukemia (ALL), also called as lymphoblastic leukemia, is one of the most common types of cancer during childhood which spreads in the body through lymph nodes, spinal cord, liver, spleen, central nervous system, amongst others. B-cell ALL, T-cell ALL, and Philadelphia chromosome-positive ALL (Ph+ ALL) are three of the most common primary types of ALL. B-cell ALL is the most common type. The treatment of patients with Ph+ ALL involves precise drugs which target the gene products.
Rising Global Incidences of Acute lymphoblastic leukemia
One of the major factors responsible for the growth of this market is the rising occurrence of ALL globally. The number of new cases being recorded each year is around 1.7 per 100,000 men & women per year. According to National Cancer Institute (NCI) study of 2014, there were estimated 82,000 people living with ALL over the United States. In addition, by 2020, it has been estimated that the number of cases of ALL should range around 0.4 to 2 per 100,000 population in the Asia-Pacific and South American countries. There is a rise in the number of cases in the Asia-Pacific region primarily due to the adoption of western lifestyles including dietary changes and sedentary lifestyles. Therefore, globally, the prevalence is expected to increase in the forecast period, which shall be the major factor for the growth of this market.
Other factors that should be taken into account are rising preference towards targeted therapy use in cancer treatment, the rise in the number of bone marrow biopsies, and increasing overall investments in research and development.
Stringent Regulatory Pathways
For many companies, the strict regulatory pathways for drug safety and marketing is one the major restrictions to reach out to the global population, which restricts the growth of this market. Several anticancer treatments are restricted during clinical trials due to high side effects and toxic effects in patients, leading to a failure in the marketing of a drug in that particular region. In several cases, the therapies are recalled even after clearance due to a wide number of side-effects being observed.
Other factors such as patent expiry of blockbuster drugs paving the way to generic companies and high cost associated with the cancer treatment impede the growth of this market.
North America to Dominate the Acute Lymphoblastic Leukemia Therapeutics Market
The acute lymphoblastic leukemia therapeutics market report is segmented by cell type, therapy type, route of administration, and geography. Based on geography, it is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.
North America is expected to dominate this market due to the rising number of cases of this disease in the region owing to genetic factors, environmental factors, and radiation. Moreover, favorable government policies, well-established healthcare infrastructure, and presence of multinational companies make this region dominant in this market. Asia-Pacific is also expected to grow at a high CAGR during the forecast period owing to several factors, such as high unmet clinical needs, huge patient pool, and the rising awareness about early diagnosis in emerging countries.
Key Developments in Acute Lymphoblastic Leukemia Therapeutics Market
- February 2018: Sanofi announced to discard the mid-stage effort on ALL therapy for the anti-CD38 antibody isatuximab.
- February 2018: Erytech Pharma broadened the scope of eryaspase (GRASPA) development for solid tumors further clinical studies in triple negative breast cancer.
Acute Lymphoblastic Leukemia Therapeutics Market Major players: Bristol Myer Squibb Company, Celegene Corporation, Eisai Co Ltd, Erytech Pharma, F. Hoffmann-La Roche Ltd, Genmab A/S, GlaxoSmithKline, Novartis AG, Pfizer Inc, and Sanofi SA, among others.
Reasons to Purchase Acute Lymphoblastic Leukemia Therapeutics Market Report
- Current and future the global acute lymphoblastic leukemia therapeutics market outlook in the developed and emerging markets
- Analyzing various perspectives of the market with the help of Porter’s five forces analysis
- Analysis on the segment that is expected to dominate the market
- Regions that are expected to witness fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of Acute Lymphoblastic Leukemia Therapeutics Market Report
- This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Acute Lymphoblastic Leukemia Therapeutics Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Acute Lymphoblastic Leukemia Therapeutics Market Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Acute Lymphoblastic Leukemia Therapeutics Market Drivers
6.1.1 Rise in the Incidences of Acute Lymphoblastic Leukemia
6.1.2 Increasing Preference to Shift Towards the Targeted Therapy Use
6.1.3 Rise in the Number of Bone Marrow Biopsies
6.1.4 Increasing Investment in Research and Development
6.2 Acute Lymphoblastic Leukemia Therapeutics Market Restraints
6.2.1 Stringent Regulatory Pathways
6.2.2 Patent Expiry of Blockbuster Drugs
6.2.3 High Cost Asscoiated with the Treatment
6.3 Acute Lymphoblastic Leukemia Therapeutics Market Opportunities
6.4 Acute Lymphoblastic Leukemia Therapeutics Market Key Challenges
7. Acute Lymphoblastic Leukemia Therapeutics Market Segmentation
7.1 Acute Lymphoblastic Leukemia Therapeutics Market By Type of Cell
7.1.1 B-cell ALL
7.1.2 T-cell ALL
7.1.3 Philadelphia chromosome: Positive (Ph+) and negative (Ph-) ALL
7.2 Acute Lymphoblastic Leukemia Therapeutics Market By Type of Therapy
22.214.171.124 Hyper - CVAD Regimen
126.96.36.199 CALGB 8811 Regimen
188.8.131.52 Linker Regimen
184.108.40.206 Nucleoside Inhibitors
7.2.2 Targeted Therapy
7.2.3 Radiation Therapy
7.2.4 Stem Cell Transplantation
7.3 Acute Lymphoblastic Leukemia Therapeutics Market By Route of Administration
7.4 Acute Lymphoblastic Leukemia Therapeutics Market By Geography
7.4.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
7.4.4 Middle East & Africa
184.108.40.206 South Africa
220.127.116.11 Rest of the Middle East & Africa
7.4.5 South America
18.104.22.168 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Acute Lymphoblastic Leukemia Therapeutics Market Key Players
9.1 Bristol Myer Squibb Company
9.2 Celegene Corporation
9.3 Eisai Co Ltd
9.4 Erytech Pharma
9.5 F. Hoffmann-La Roche Ltd
9.6 Genmab A/S
9.8 Novartis AG
9.9 Pfizer Inc
9.10 Sanofi SA
*List not exhaustive
10. Acute Lymphoblastic Leukemia Therapeutics Market Future